Goldman Sachs, JMP Securities and Piper Sandler all initiated coverage of Sagimet Biosciences with bullish ratings, citing the biotech's promising drug candidate denifanstat for the treatment of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results